Low-dose radiation plus immunotherapy for cancer with liver spread
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial tests whether giving low-dose radiation to liver tumors along with immunotherapy can help people with certain advanced cancers that have spread to the liver. It may improve how well the treatment works for people whose cancer has stopped responding to earlier treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced non-small cell lung cancer, colorectal cancer, or pancreatic cancer that has progressed after prior treatment.
- Your cancer has spread to the liver, with at least one measurable liver tumor.
- You are able to perform daily activities with some help (ECOG 0-2).
- Your blood counts and liver/kidney function are within acceptable limits.
- You have not had radiation to the abdomen or pelvis in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a low dose of radiation to the liver can make standard immunotherapy work better for people with non-small cell lung cancer or melanoma that has spread to the liver.
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
This trial studies whether adding targeted radiation to the liver (small-area, high-precision radiation) can help people with stage IV non-small cell lung cancer. Participants also start standard “anti–PD-1/PD-L1” immunotherapy (with chemotherapy in some cases).
This trial tests a new drug that helps the immune system fight cancer, combined with a special type of radiation therapy, for people with esophageal, lung, or cervical cancer that has progressed after initial treatment.
This trial tests a combination therapy that includes an immunotherapy drug (called anti-PD-1) for people with rectal cancer that has spread to the liver or lungs. The goal is to see if this treatment can help shrink or control the cancer, and it may be an option if you haven't had treatment yet.
This trial combines low-dose radiation with an immunotherapy drug (pucotenlimab) and standard treatment for advanced pancreatic cancer. It aims to see if this triple therapy can help control the cancer without using a PD-1/PD-L1 inhibitor before.
Hear when a new Liver Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.